nasdaq:dova
|
11042846
|
Jan 5th, 2022 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Jan 5th, 2022 09:14AM
|
Jan 5th, 2022 09:14AM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Jan 4th, 2022 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Jan 3rd, 2022 09:36PM
|
Jan 3rd, 2022 09:36PM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Jan 3rd, 2022 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Jan 3rd, 2022 09:02AM
|
Jan 3rd, 2022 09:02AM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Jan 2nd, 2022 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Jan 2nd, 2022 03:38PM
|
Jan 2nd, 2022 03:38PM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Jan 1st, 2022 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Jan 1st, 2022 05:30PM
|
Jan 1st, 2022 05:30PM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Dec 31st, 2021 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Dec 31st, 2021 01:51PM
|
Dec 31st, 2021 01:51PM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Dec 30th, 2021 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Dec 30th, 2021 12:21PM
|
Dec 30th, 2021 12:21PM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Dec 29th, 2021 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Dec 29th, 2021 12:43PM
|
Dec 29th, 2021 12:43PM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Dec 28th, 2021 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Dec 28th, 2021 09:18AM
|
Dec 28th, 2021 09:18AM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|
nasdaq:dova
|
11042846
|
Dec 27th, 2021 12:00AM
|
Dova Pharmaceuticals
|
9.5K
|
47.00
|
Open
|
Biotechnology
|
Dec 27th, 2021 11:31AM
|
Dec 27th, 2021 11:31AM
|
Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve patients' health and well-being in this community. The US FDA approved Dova's lead drug product in May 2018, and in June 2019, the FDA approved a second indication. In June 2019, Dova also received its first approval in the EU. Dova is headquartered in Durham, North Carolina. The company is a wholly-owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
|
Open
|
|
Open
|
240 Leigh Farm Road, Suite 245
|
Durham
|
NC
|
US
|
27707
|
|
Dova Pharmaceuticals
|
|
|